메뉴 건너뛰기




Volumn 44, Issue 3, 2015, Pages 517-530

Bone Health and Osteoporosis

Author keywords

Bone loss; Bone mineral density; Calcium; DXA; Fracture; Menopause; Osteoporosis; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; DENOSUMAB; ESTROGEN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D; ZOLEDRONIC ACID;

EID: 84940042264     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2015.05.002     Document Type: Review
Times cited : (145)

References (36)
  • 2
    • 0030969826 scopus 로고    scopus 로고
    • Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: a population-based study
    • Khosla S., Atkinson E.J., Melton L.J., et al. Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: a population-based study. J Clin Endocrinol Metab 1997, 82(5):1522-1527.
    • (1997) J Clin Endocrinol Metab , vol.82 , Issue.5 , pp. 1522-1527
    • Khosla, S.1    Atkinson, E.J.2    Melton, L.J.3
  • 3
    • 84940086823 scopus 로고    scopus 로고
    • Accessed December 9, 2014.
    • International Society for Clinical Densitometry Official Positions - Adult. 2013. Available at: . Accessed December 9, 2014. http://www.iscd.org/official-positions/2013-iscd-official-positions-adult.
    • (2013)
  • 6
    • 84940086824 scopus 로고    scopus 로고
    • Accessed December 9, 2014.
    • US Preventive Services Task Force. Screening for osteoporosis recommendation statement. 2011. Available at: . Accessed December 9, 2014. http://www.uspreventiveservicestaskforce.org/uspstf10/osteoporosis/osteors.htm.
    • (2011)
  • 7
    • 84940086825 scopus 로고    scopus 로고
    • Accessed December 9, 2014.
    • National Ostoporosis Foundation. 2013 Clinician's guide to prevention and treatment of osteoporosis. Available at: . Accessed December 9, 2014. http://nof/public/content/resource/913/files/580.pdf.
  • 8
    • 80052725039 scopus 로고    scopus 로고
    • Institute of Medicine, Washington, DC, Available at:, Accessed December 9, 2014
    • Ross C.A., Taylor C.L., Yaktine A.L., et al. IOM report on calcium and vitamin D 2010, Institute of Medicine, Washington, DC, Available at:, Accessed December 9, 2014. http://www.iom.edu/vitaminD.
    • (2010) IOM report on calcium and vitamin D
    • Ross, C.A.1    Taylor, C.L.2    Yaktine, A.L.3
  • 9
    • 6344250905 scopus 로고    scopus 로고
    • Dietary protein intake and risk of osteoporotic hip fracture in elderly residents of Utah
    • Wengreen H.J., Munger R.G., West N.A., et al. Dietary protein intake and risk of osteoporotic hip fracture in elderly residents of Utah. J Bone Miner Res 2004, 19(4):537-545.
    • (2004) J Bone Miner Res , vol.19 , Issue.4 , pp. 537-545
    • Wengreen, H.J.1    Munger, R.G.2    West, N.A.3
  • 10
    • 0033696402 scopus 로고    scopus 로고
    • Effect of dietary protein on bone loss in elderly men and women: the Framingham Osteoporosis Study
    • Hannan M.T., Tucker K.L., Dawson-Hughes B., et al. Effect of dietary protein on bone loss in elderly men and women: the Framingham Osteoporosis Study. J Bone Miner Res 2000, 15(12):2504-2512.
    • (2000) J Bone Miner Res , vol.15 , Issue.12 , pp. 2504-2512
    • Hannan, M.T.1    Tucker, K.L.2    Dawson-Hughes, B.3
  • 11
    • 0031661031 scopus 로고    scopus 로고
    • Dietary protein affects intestinal calcium absorption
    • Kerstetter J.E., O'Brien K.O., Insogna K.L. Dietary protein affects intestinal calcium absorption. Am J Clin Nutr 1998, 68(4):859-865.
    • (1998) Am J Clin Nutr , vol.68 , Issue.4 , pp. 859-865
    • Kerstetter, J.E.1    O'Brien, K.O.2    Insogna, K.L.3
  • 12
    • 0031817494 scopus 로고    scopus 로고
    • Physical activity and osteoporotic fracture risk in older women. Study of Osteoporotic Fractures Research Group
    • Gregg E.W., Cauley J.A., Seeley D.G., et al. Physical activity and osteoporotic fracture risk in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1998, 129(2):81-88.
    • (1998) Ann Intern Med , vol.129 , Issue.2 , pp. 81-88
    • Gregg, E.W.1    Cauley, J.A.2    Seeley, D.G.3
  • 13
    • 0036048481 scopus 로고    scopus 로고
    • Exercise for preventing and treating osteoporosis in postmenopausal women
    • CD000333
    • Bonaiuti D., Shea B., Iovine R., et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev 2002, (3). CD000333.
    • (2002) Cochrane Database Syst Rev , Issue.3
    • Bonaiuti, D.1    Shea, B.2    Iovine, R.3
  • 14
    • 0029884643 scopus 로고    scopus 로고
    • Bisphosphonates: mechanisms of action
    • Rodan G.A., Fleisch H.A. Bisphosphonates: mechanisms of action. J Clin Invest 1996, 97(12):2692-2696.
    • (1996) J Clin Invest , vol.97 , Issue.12 , pp. 2692-2696
    • Rodan, G.A.1    Fleisch, H.A.2
  • 15
    • 0029133135 scopus 로고
    • Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
    • Hughes D.E., Wright K.R., Uy H.L., et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995, 10(10):1478-1487.
    • (1995) J Bone Miner Res , vol.10 , Issue.10 , pp. 1478-1487
    • Hughes, D.E.1    Wright, K.R.2    Uy, H.L.3
  • 16
    • 33947109369 scopus 로고    scopus 로고
    • Bisphosphonates: mode of action and pharmacology
    • Russell R.G. Bisphosphonates: mode of action and pharmacology. Pediatrics 2007, 119(Suppl 2):S150-S162.
    • (2007) Pediatrics , vol.119 , Issue.SUPPL 2 , pp. S150-S162
    • Russell, R.G.1
  • 17
    • 51349163043 scopus 로고    scopus 로고
    • Bisphosphonates: mechanism of action and role in clinical practice
    • Drake M.T., Clarke B.L., Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008, 83(9):1032-1045.
    • (2008) Mayo Clin Proc , vol.83 , Issue.9 , pp. 1032-1045
    • Drake, M.T.1    Clarke, B.L.2    Khosla, S.3
  • 18
    • 0004851872 scopus 로고    scopus 로고
    • Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group
    • Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348(9041):1535-1541.
    • (1996) Lancet , vol.348 , Issue.9041 , pp. 1535-1541
    • Black, D.M.1    Cummings, S.R.2    Karpf, D.B.3
  • 19
    • 0032583492 scopus 로고    scopus 로고
    • Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial
    • Cummings S.R., Black D.M., Thompson D.E., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998, 280(24):2077-2082.
    • (1998) JAMA , vol.280 , Issue.24 , pp. 2077-2082
    • Cummings, S.R.1    Black, D.M.2    Thompson, D.E.3
  • 20
    • 0033552255 scopus 로고    scopus 로고
    • Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group
    • Harris S.T., Watts N.B., Genant H.K., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999, 282(14):1344-1352.
    • (1999) JAMA , vol.282 , Issue.14 , pp. 1344-1352
    • Harris, S.T.1    Watts, N.B.2    Genant, H.K.3
  • 21
    • 0035253489 scopus 로고    scopus 로고
    • Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group
    • McClung M.R., Geusens P., Miller P.D., et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001, 344(5):333-340.
    • (2001) N Engl J Med , vol.344 , Issue.5 , pp. 333-340
    • McClung, M.R.1    Geusens, P.2    Miller, P.D.3
  • 22
    • 4544262219 scopus 로고    scopus 로고
    • Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
    • Chesnut I.C., Skag A., Christiansen C., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004, 19(8):1241-1249.
    • (2004) J Bone Miner Res , vol.19 , Issue.8 , pp. 1241-1249
    • Chesnut, I.C.1    Skag, A.2    Christiansen, C.3
  • 23
    • 34247866550 scopus 로고    scopus 로고
    • Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
    • Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356(18):1809-1822.
    • (2007) N Engl J Med , vol.356 , Issue.18 , pp. 1809-1822
    • Black, D.M.1    Delmas, P.D.2    Eastell, R.3
  • 24
    • 84878164987 scopus 로고    scopus 로고
    • Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis
    • Gedmintas L., Solomon D.H., Kim S.C. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res 2013, 28(8):1729-1737.
    • (2013) J Bone Miner Res , vol.28 , Issue.8 , pp. 1729-1737
    • Gedmintas, L.1    Solomon, D.H.2    Kim, S.C.3
  • 25
    • 34848841461 scopus 로고    scopus 로고
    • Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research
    • Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22(10):1479-1491.
    • (2007) J Bone Miner Res , vol.22 , Issue.10 , pp. 1479-1491
    • Khosla, S.1    Burr, D.2    Cauley, J.3
  • 26
    • 33845890326 scopus 로고    scopus 로고
    • Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial
    • Black D.M., Schwartz A.V., Ensrud K.E., et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006, 296(24):2927-2938.
    • (2006) JAMA , vol.296 , Issue.24 , pp. 2927-2938
    • Black, D.M.1    Schwartz, A.V.2    Ensrud, K.E.3
  • 27
    • 84861668653 scopus 로고    scopus 로고
    • Continuing bisphosphonate treatment for osteoporosis-for whom and for how long?
    • Black D.M., Bauer D.C., Schwartz A.V., et al. Continuing bisphosphonate treatment for osteoporosis-for whom and for how long?. N Engl J Med 2012, 366(22):2051-2053.
    • (2012) N Engl J Med , vol.366 , Issue.22 , pp. 2051-2053
    • Black, D.M.1    Bauer, D.C.2    Schwartz, A.V.3
  • 28
    • 84856184102 scopus 로고    scopus 로고
    • The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
    • Black D.M., Reid I.R., Boonen S., et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012, 27(2):243-254.
    • (2012) J Bone Miner Res , vol.27 , Issue.2 , pp. 243-254
    • Black, D.M.1    Reid, I.R.2    Boonen, S.3
  • 29
    • 0037125379 scopus 로고    scopus 로고
    • Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial
    • Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002, 288(3):321-333.
    • (2002) JAMA , vol.288 , Issue.3 , pp. 321-333
    • Rossouw, J.E.1    Anderson, G.L.2    Prentice, R.L.3
  • 30
    • 0033581212 scopus 로고    scopus 로고
    • Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators
    • Ettinger B., Black D.M., Mitlak B.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999, 282(7):637-645.
    • (1999) JAMA , vol.282 , Issue.7 , pp. 637-645
    • Ettinger, B.1    Black, D.M.2    Mitlak, B.H.3
  • 31
    • 0035837553 scopus 로고    scopus 로고
    • Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
    • Neer R.M., Arnaud C.D., Zanchetta J.R., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344(19):1434-1441.
    • (2001) N Engl J Med , vol.344 , Issue.19 , pp. 1434-1441
    • Neer, R.M.1    Arnaud, C.D.2    Zanchetta, J.R.3
  • 32
    • 69049083492 scopus 로고    scopus 로고
    • Denosumab for prevention of fractures in postmenopausal women with osteoporosis
    • Cummings S.R., San Martin J., McClung M.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361(8):756-765.
    • (2009) N Engl J Med , vol.361 , Issue.8 , pp. 756-765
    • Cummings, S.R.1    San Martin, J.2    McClung, M.R.3
  • 33
    • 84872332488 scopus 로고    scopus 로고
    • Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial
    • McClung M.R., Lewiecki E.M., Geller M.L., et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int 2013, 24(1):227-235.
    • (2013) Osteoporos Int , vol.24 , Issue.1 , pp. 227-235
    • McClung, M.R.1    Lewiecki, E.M.2    Geller, M.L.3
  • 34
    • 0033829969 scopus 로고    scopus 로고
    • A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group
    • Chesnut C.H., Silverman S., Andriano K., et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000, 109(4):267-276.
    • (2000) Am J Med , vol.109 , Issue.4 , pp. 267-276
    • Chesnut, C.H.1    Silverman, S.2    Andriano, K.3
  • 35
    • 0026671983 scopus 로고
    • Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study
    • Overgaard K., Hansen M.A., Jensen S.B., et al. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992, 305(6853):556-561.
    • (1992) BMJ , vol.305 , Issue.6853 , pp. 556-561
    • Overgaard, K.1    Hansen, M.A.2    Jensen, S.B.3
  • 36
    • 0023794243 scopus 로고
    • Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment
    • Civitelli R., Gonnelli S., Zacchei F., et al. Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. J Clin Invest 1988, 82(4):1268-1274.
    • (1988) J Clin Invest , vol.82 , Issue.4 , pp. 1268-1274
    • Civitelli, R.1    Gonnelli, S.2    Zacchei, F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.